CLRB Cellectar Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CLRB

Price (delayed)

$2.1

Market cap

$75.28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.08

Enterprise value

$35.8M

Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. ...

Highlights
CLRB's quick ratio is up by 35% YoY
The company's EPS rose by 19% YoY
Cellectar Biosciences's net income has shrunk by 64% YoY and by 34% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cellectar.com
Peers: GLYC FBIO

Key stats

What are the main financial stats of CLRB
Market
Shares outstanding
35.85M
Market cap
$75.28M
Enterprise value
$35.8M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.59
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$51.04M
EBITDA
-$50.75M
Free cash flow
-$39.44M
Per share
EPS
-$3.08
Free cash flow per share
-$1.34
Book value per share
$0.81
Revenue per share
$0
TBVPS
$1.46
Balance sheet
Total assets
$42.91M
Total liabilities
$16.74M
Debt
$548,343
Equity
$26.17M
Working capital
$25.1M
Liquidity
Debt to equity
0.02
Current ratio
2.54
Quick ratio
2.46
Net debt/EBITDA
0.78
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-245.6%
Return on equity
-1,855.6%
Return on invested capital
N/A
Return on capital employed
-191.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLRB stock price

How has the Cellectar Biosciences stock price performed over time
Intraday
0.48%
1 week
0%
1 month
12.9%
1 year
-4.55%
YTD
-24.19%
QTD
-16%

Financial performance

How have Cellectar Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$42.26M
Net income
-$50.98M
Gross margin
N/A
Net margin
N/A
Cellectar Biosciences's net income has shrunk by 64% YoY and by 34% QoQ
Cellectar Biosciences's operating income has decreased by 35% YoY and by 8% from the previous quarter

Growth

What is Cellectar Biosciences's growth rate over time

Valuation

What is Cellectar Biosciences stock price valuation
P/E
N/A
P/B
2.59
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 19% YoY
The price to book (P/B) is 52% higher than the 5-year quarterly average of 1.7

Efficiency

How efficient is Cellectar Biosciences business performance
The company's return on assets has shrunk by 61% YoY but it rose by 11% QoQ

Dividends

What is CLRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLRB.

Financial health

How did Cellectar Biosciences financials performed over time
The total assets is 156% more than the total liabilities
The total assets has soared by 189% YoY
The total liabilities has soared by 123% YoY and by 25% from the previous quarter
The company's debt is 98% lower than its equity
The company's debt to equity has surged by 105% QoQ but it has shrunk by 75% YoY
The company's debt fell by 9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.